trending Market Intelligence /marketintelligence/en/news-insights/trending/d6Bn-fnGF5KDFWQFxGVLkA2 content esgSubNav
In This List

Acorda to appeal ruling invalidating multiple sclerosis drug patents

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Acorda to appeal ruling invalidating multiple sclerosis drug patents

Acorda Therapeutics Inc. plans to appeal the U.S. District Court of Delaware ruling that invalidated four U.S. patents related to its multiple sclerosis drug AMPYRA.

The court, meanwhile, upheld a patent related to the drug, which is set to expire in July 2018.

The U.S. Patent and Trademark Office had previously upheld these four patents which were challenged via the inter partes review process.